Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Business Wire
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a s
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure…
-
Business24 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News23 hours agoDingoes bite 3 women on K’gari
-
Noosa News14 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs
-
Noosa News23 hours agoNoosa MP calls for solutions to curb reckless electric bike usage